Aclarion, Inc. · NASDAQ:ACON
Aclarion — Investor Presentation (April 2025)
22 slides from Aclarion's investor presentation, Apr 23, 2025
Slide 1: Better Data Better Care
Better Data Better Care NASDAQ: ACON
Slide 2: Disclaimer
Aclarion 2025 2 Disclaimer The information in this material is provided for general information purposes only and does not take into account the investment objectives, financial situation and particular needs of any individual or entity . This presentation contains forward - looking statements withi
Slide 3: Strategic and Financial Highlights
Aclarion 2025 3 Strategic and Financial Highlights N early $14.6 million in cash on hand as of 10K filed on 4/9/2025 > cash runway into Q3 2026 Clean cap table, zero debt, no preferred shares outstanding, no near - term warrant overhang Fully Nasdaq compliant, meeting both bid price and shar
Slide 4: Low Back Pain: A Global Epidemic
Aclarion 2025 4 Low Back Pain: A Global Epidemic 266M p eople suffer from Chronic Low Back Pain 1 • 20 - 30% reduction in work productivity 5 • Absenteeism and work - related disability costing $100 - 200B / year 5 • Leading cause of opioid addiction INDIRECT COSTS • 635K spinal fusion surgeries / y
Slide 5: Market Opportunity
Aclarion 2025 5 $10B 1 U.S. lumbar fusion & disc replacement market – actionable now 635,000 x $950 = $603M Nociscan TAM $40B 2 U.S. lumbar spine market (fusion & non - fusion surgery plus presurgical care) – expansion $135B 3 U.S. low back & neck pain market – ultimate market Market Opportunity 1 M
Slide 6: Physicians Quandary
Aclarion 2025 6 Physicians Quandary Patient is in pain, but which disc is the cause? High surgical decision variability Expensive Poor Outcomes Low value Current Imaging Approaches Fail to Identify Discogenic Sources of Pain
Slide 7: Solution
Aclarion 2025 7 Solution Technology labels each disc as painful or pain free Personalized treatment path is optimized Lower cost Better outcomes Higher value care
Slide 8: Nociscan Product
Aclarion 2025 8 Nociscan Product Spectroscopy analyzes the chemical composition of tissue Proprietary signal processing software transforms raw spectral data into clear biomarkers Acidic pain markers 1 • Alanine (LAAL = lactic acid + alanine) • Lactic Acid (LAC) • Propionate (PRO) Structural integri
Slide 9: Clear Delineation Between Pain & No Pain
Aclarion 2025 9 Clear Delineation Between Pain & No Pain 1 Freemont AJ, Rheumatology (2009) 48:5 – 10. 2 Immke and McCleskey, Nat Neurosci . (2001) Sep;4(9):869 - 70 Six ratios for each disc • Pain markers in the numerator (3) • Structural integrity markers in the denominator (2) • Differentially we
Slide 10: Streamlined, Easy-to-Interpret Physician Report
Aclarion 2025 10 Streamlined, Easy - to - Interpret Physician Report Translating complex radiographic information into a clinically useful report
Slide 11: Intellectual Property
Aclarion 2025 11 Intellectual Property 24 Issued U.S. Patents 17 Issued International Patents Post processing technologies to more reliably & accurately measure biomarkers from MRS spectra Exclusive worldwide license from UCSF for intervertebral disc biomarkers & ratios Use of proprietary biomarkers
Slide 12: Provocative Discogram vs. Nociscan Virtual Discogram
Aclarion 2025 12 Provocative Discogram Nociscan Virtual Discogram Invasive Non - invasive Subjective Objective Severely painful by design No pain Lumbar CT = ~10x radiation of chest x - ray No radiation Additional exam after MRI Can be added to a standard lumbar MRI Half - day procedure with days ou
Slide 13: Better Surgical Outcomes
Aclarion 2025 13 Published in the European Spine Journal in 2019 & 2023 Better Surgical Outcomes Gornet study published in European Spine Journal 1 139 cLBP patients with 73 undergoing surgery 85 % of patients improved if all Nociscan positive discs treated 2 63 % of patients improved if a Nociscan
Slide 14: CLARITY Pivotal Trial
Aclarion 2025 14 CLARITY Pivotal Trial Multi - site, randomized, controlled trial evaluating the outcomes of surgical patients when the surgeon has access to Nociscan data compared to when the surgeon does not have access to Nociscan data Principal Investigator & Anchor Site • 300 patients estimated
Slide 15: Clinical Evidence Plan
Aclarion 2025 15 Clinical Evidence Plan 7 ONGOING CLINICAL TRIALS FUTURE EVIDENCE • Nociscan vs. traditional surgical planning • Clinical utility & outcomes • Real - world experience • Investigator Initiated (Free to Aclarion ) 8 PEER - REVIEWED PUBLICATIONS EVIDENCE TO DATE 250+ PATIENTS STUDIED Ev
Slide 16: UK Payer Coverage
Aclarion 2025 16 *Source: The Guardian, 04/24 UK Payer Coverage Multiple Private Medical Insurers Covering Nociscan UK Private Hospital Revenue* Private Medical Insurers Covering Nociscan In conjunction with efforts by our customer, The London Clinic, Nociscan is now covered by three of the top four
Slide 17: London Clinic: Launch Full Commercial Effort
Aclarion 2025 17 London Clinic: Launch Full Commercial Effort Strong physician advocates Strategic, marketing initiatives Rapid and deep product adoption STRATEGY Leverage KOLs to increase market awareness and usage of Nociscan TACTICS Aclarion Direct Dinner Symposia Physician Training Direct Incent
Slide 18: Reimbursement Landscape
Aclarion 2025 18 Reimbursement Landscape Description CPT Code MRS, determination & localization of discogenic pain (cervical, thoracic, or lumbar); acquisition of single voxel data, per disc , in ≥3 discs – PAID TO IMAGING CENTER 0609T MRS, determination & localization of discogenic pain (cervical,
Slide 19: Key Opinion Leader Development & Advocacy
Aclarion 2025 19 Key Opinion Leader Development & Advocacy John Keller MD Juan Uribe MD Sig Berven MD Christopher Ames MD George Frey MD Grand Rapids, MI Phoenix, AZ San Francisco, CA San Francisco, CA Denver, CO Region Dean Karahalios MD Apesh Patel MD Greg Basil MD Roger Hartl MD Eric Potts MD Chi
Slide 20: Management Team
Aclarion 2025 20 Management Team Executive Chairman JEFF THRAMANN, MD CEO & Director BRENT NESS CFO JOHN LORBIECKI Chief Strategy Officer RYAN BOND • Serial entrepreneur with multiple exits • Over 100 US & International patents • Public company board experience • Neurosurgeon & spine fellow • U.S. M
Slide 21: Key Takeaways
Aclarion 2025 21 Key Takeaways 1 Dieleman JL, JAMA (2020) 323(9) LARGEST HEALTHCARE MARKET • Address a leading cause of healthcare expenditures in the U.S. – up to $134.5B market 1 • Industry 1st noninvasive diagnostic with strong value proposition for patients, doctors, imaging centers and payers F
Slide 22: Investor Relations Contact
www.aclarion.com Investor Relations Kirin Smith, President ksmith@pcgadvisory.com Ph: 646.823.8656